Next, we examined the effect of erlotinib plus prednisone in a Patient-Derived Xenograft (PDX) model of NSCLC with KRAS G13C mutant and without activating EGFR mutations (HCC4087). This evidence concerns the gene EGFR and non-small cell lung carcinoma.